Plasma urocortin in acute myocardial infarction patients

European Journal of Clinical Investigation

Volumn 40, Issue 10, 2010, Pages 874-882

  Phrommintikul, Arintaya ^a,b   Sivasinprasasn, Sivaporn ^a,c   Lailerd, Narissara ^a,c   Chattipakorn, Siriporn ^a,d   Kuanprasert, Srun ^a,b   Chattipakorn, Nipon ^a,b,c,e  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b Cardiology Division   (United States)

^c Faculty of Medicine   (United States)

^d Faculty of Dentistry   (United States)

^e CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Acute myocardial infarction; cardiac function; cardiac markers; urocortin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; UROCORTIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; UROCORTINS;

EID: 77956534017     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02343.x     Document Type: Article

References (33)

1. Ilva T, Eriksson S, Lund J, Porela P, Mustonen H, Pettersson K et al. Improved early risk stratification and diagnosis of myocardial infarction, using a novel troponin I assay concept. Eur J Clin Invest 2005 35 : 112 116.
2. Kondo H, Hojo Y, Tsuru R, Nishimura Y, Shimizu H, Takahashi N et al. Elevation of plasma granzyme B levels after acute myocardial infarction. Circ J 2009 73 : 503 507.
3. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004 25 : 1187 1196.
4. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002 105 : 1760 1763.
5. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 2004 106 : 383 388.
6. Knight RA, Chen-Scarabelli C, Yuan Z, McCauley RB, Di Rezze J, Scarabelli GM et al. Cardiac release of urocortin precedes the occurrence of irreversible myocardial damage in the rat heart exposed to ischemia/reperfusion injury. FEBS Lett 2008 582 : 984 990.
7. Boonprasert P, Lailerd N, Chattipakorn N. Urocortins in heart failure and ischemic heart disease. Int J Cardiol 2008 127 : 307 312.
8. Huang Y, Yao XQ, Lau CW, Chan YC, Tsang SY, Chan FL. Urocortin and cardiovascular protection. Acta Pharmacol Sin 2004 25 : 257 265.
9. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000 279 : H3031 9.
10. Parkes DG, May CN. Urocortin: a Novel Player in Cardiac Control. News Physiol Sci 2000 15 : 264 268.
11. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 2002 40 : 1495 1505.
12. Brar BK, Stephanou A, Okosi A, Lawrence KM, Knight RA, Marber MS et al. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol Cell Endocrinol 1999 158 : 55 63.
13. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 2000 275 : 8508 8514.
14. Przyklenk K, Kloner RA. Ischemic preconditioning: exploring the paradox. Prog Cardiovasc Dis 1998 40 : 517 547.
15. Cave AC, Hearse DJ. Ischaemic preconditioning and contractile function: studies with normothermic and hypothermic global ischaemia. J Mol Cell Cardiol 1992 24 : 1113 1123.
16. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc Res 1990 24 : 1020 1023.
17. Sharma A, Singh M. Effect of ethylisopropyl amiloride, a Na+ - H+ exchange inhibitor, on cardioprotective effect of ischaemic and angiotensin preconditioning. Mol Cell Biochem 2000 214 : 31 8.
18. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010 40 : 35 53.
19. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007 28 : 2525 2538.
20. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006 10 : R73.
21. Grossini E, Molinari C, Mary DA, Marino P, Vacca G. The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric-oxide-dependent. Eur J Pharmacol 2008 578 : 242 248.
22. Miki I, Seya K, Motomura S, Furukawa K. Role of corticotropin-releasing factor receptor type 2 beta in urocortin-induced vasodilation of rat aortas. J Pharmacol Sci 2004 96 : 170 176.
23. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 2001 169 : 177 183.
24. Lefer AM, Tsao PS, Lefer DJ, Ma XL. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J 1991 5 : 2029 2034.
25. Bode C, Zirlik A. STEMI and NSTEMI: the dangerous brothers. Eur Heart J 2007 28 : 1403 1404.
26. Weber M, Kleine C, Keil E, Rau M, Berkowitsch A, Elsaesser A et al. Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 2006 95 : 270 280.
27. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002 23 : 1177 1189.
28. Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002 90 : 358 363.
29. Srimahachota S, Kanjanavanit R, Boonyaratavej S, Boonsom W, Veerakul G, Tresukosol D. Demographic, management practices and in-hospital outcomes of Thai Acute Coronary Syndrome Registry (TACSR): the difference from the Western world. J Med Assoc Thai 2007 90 (Suppl 1 1 11.
30. Grech ED, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ 2003 326 : 1259 1261.
31. Maewal P, de Lemos JA. Natriuretic peptide hormone measurement in acute coronary syndromes. Heart Fail Rev 2003 8 : 365 368.
32. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998 97 : 1921 1929.
33. Cameron SJ, Sokoll LJ, Laterza OF, Shah S, Green GB. A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes. Clin Chim Acta 2007 376 (1-2 168 173.